Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial

The Lancet

Volumn 381, Issue 9867, 2013, Pages 661-669

  Christiansen, Evald Høj ^a   Jensen, Lisette Okkels ^b   Thayssen, Per ^b   Tilsted, Hans Henrik ^c   Krusell, Lars Romer ^a   Hansen, Knud Nørregaard ^b   Kaltoft, Anne ^a   Maeng, Michael ^a   Kristensen, Steen Dalby ^a   Bøtker, Hans Erik ^a   Terkelsen, Christian Juhl ^a   Villadsen, Anton Boel ^c   Ravkilde, Jan ^c   Aarøe, Jens ^c   Madsen, Morten ^a   Thuesen, Leif ^a   Lassen, Jens Flensted ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER; RAPAMYCIN; UMIROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTERY DIAMETER; ARTICLE; BIODEGRADABILITY; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS;

EID: 84874441236     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61962-X     Document Type: Article

References (29)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
4. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
5. Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010; 5: 898-905.
6. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
7. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-99.
8. Ostojic M, Sagic D, Jung R, et al. The pharmacokinetics of biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008; 72: 901-08.
9. Ostojic M, Sagic D, Beleslin B, et al. First clinical comparison of Nobori-biolimus A9 eluting stents with Cypher-sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. EuroIntervention 2008; 3: 574-79.
10. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-48.
11. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163-73.
12. Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus-versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011; 58: 1325-31.
13. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010; 375: 1090-99.
14. Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012; 125: 1246-55.
15. Schmidt M, Maeng M, Jakobsen CJ, et al. Existing data sources for clinical epidemiology: the Western Denmark Heart Registry. Clin Epidemiol 2010; 2: 137-44.
16. Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009; 53: 658-64.
17. Moher D, Schulz KF, Altman D, for the CONSORT group. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore (NY) 2005; 1: 40-45.
18. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-38.
19. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
20. Andersen TF, Madsen M, Jørgensen J, Mellemkjaer L, Olsen J. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-68.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
22. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999; 46: 354-57.
23. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
24. Ruygrok PN, Melkert R, Morel MA, et al, for the Benestent II Investigators. Does angiography six months after coronary intervention influence management and outcome? J Am Coll Cardiol 1999; 34: 1507-11.
25. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; published online Jan 30. http://dx.doi.org/10.1016/S0140-6736(12)61852-2.
26. Danzi GB, Chevalier B, Urban P, et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention 2012; 8: 109-16.
27. Danzi GB. DES with biodegradable polymer for the treatment of complex patients: three-year outcome. EuroPCR; Paris, France; May 17, 2012.
28. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33: 1214-22.
29. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402.